logo
Renault boss quits after warning of threat from Chinese rivals

Renault boss quits after warning of threat from Chinese rivals

Telegraph5 hours ago

The boss of French state-backed car giant Renault has quit unexpectedly after warning that European manufacturers were struggling to compete with cut-price Chinese rivals.
Renault announced on Sunday night that Luca de Meo would step down after five years at the helm of the French car company. He will reportedly join Kering, the luxury goods conglomerate behind brands including Yves Saint Laurent and Gucci.
Mr De Meo said: 'There comes a time in one's life when one knows the job is done.'
The shock resignation, which will come into effect in mid-July, came just days after Mr De Meo gave an update to Renault's board on his latest five-year plan.
The new strategy, dubbed 'Futurama', covers plans for future models as well as potential diversification into new areas including defence.
Blindsided
Mr De Meo's departure is thought to have blindsided members of Renault's board. Shares in Renault, whose biggest shareholder is the French state with a 15pc stake, dropped 8pc on Monday.
Mr De Meo, an Italian car executive who previously held senior roles at Volkswagen, joined Renault in 2020.
He was tasked with steering the carmaker through a pandemic-induced sales slump, which prompted a record €8bn (£6.2bn) loss. During his tenure, Mr De Meo carried out major job cuts and reduced the company's production capacity worldwide.
But alongside its domestic rivals, Renault is now battling a slowdown in sales amid growing competition in the electric vehicle (EV) market from cheap Chinese rivals.
Mr De Meo has repeatedly called for the EU to relax regulations to help the bloc compete, while saying the industry should 'find a deal' with China.
The comments risked putting the executive at loggerheads with Emmanuel Macron, whose presidential car is made by Renault. Mr Macron split with his German counterpart last year when he backed EU tariffs on Chinese EVs.
Despite the threat from China, Renault has remained relatively insulated from Donald Trump's car tariffs thanks to the company's heavy focus on European markets.
Mr De Meo's resignation is the second high-profile departure from Europe's car industry in recent months. Carlos Tavares, chief executive of Citroen and Vauxhall owner Stellantis, stood down at the end of last year.
Leadership vacuum
The looming leadership vacuum will pose a challenge to Jean-Dominique Senard, Renault chairman, a seasoned industrialist who joined the carmaker in the wake of the high-profile arrest of Carlos Ghosn, the former chief executive.
Renault said it had already started the process of appointing a new chief executive 'based on the already defined succession plan'.
Mr Senard said: 'For five years, Luca de Meo has worked to restore Renault Group to its rightful place. Under his leadership, our company has returned to a healthy foundation, boasts an impressive range of products and has resumed growth.
'Besides being an exceptional captain of industry, Luca de Meo is also a creative, committed, passionate and inspiring individual.'
Mr De Meo is now poised to join Kering at a torrid time for the luxury goods giant as waning demand among Chinese shoppers has hit sales.
Gucci, the group's largest brand by revenues and profits, has been a particular laggard as wealthy shoppers have shunned its loud designs in favour of more minimalist luxury styles.
Shares in Kering jumped 9pc on reports the company is planning to name Mr De Meo as its new boss. However, they remain down by more than two thirds in the last two years.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump to force NHS to pay for wonder drugs
Trump to force NHS to pay for wonder drugs

Telegraph

time37 minutes ago

  • Telegraph

Trump to force NHS to pay for wonder drugs

NHS patients have been given new hope of accessing wonder drugs previously blocked in Britain as Donald Trump pressures the health service to spend more with US suppliers. Ministers are understood to be reviewing the value-for-money rules that govern which drugs the NHS can buy, amid demands from the Trump administration for the UK to be more welcoming to US pharmaceutical companies. Under the trade agreement signed between the two nations earlier this year, the Government agreed to 'endeavour to improve the overall environment for pharmaceutical companies operating in the UK'. Earlier this week, The Telegraph revealed that this could result in the NHS paying more for US drugs to see off criticism of the differences in medicine prices between the two nations. However, it is understood that discussions include not only paying more for treatments already supplied on the NHS but also making it easier for US drug giants to sell their most cutting-edge treatments to the health service. It follows a wave of high-profile rejections of so-called 'wonder' drugs in recent years. The National Institute of Health and Care Excellence (Nice), which approves new NHS drugs for purchase, has blocked treatments including one which stopped the progression of Alzheimer's disease and another that doubled the life expectancy for terminal breast cancer patients. Nice has rejected them based on assessments of how long they would extend a patient's lifespan and improve quality of life. To qualify under Nice rules a new treatment must deliver one extra year of perfect health, or longer for less perfect health, for no more than £30,000. This figure has not increased in line with inflation since 1999. If it had, it would be just over £53,000. Nice has maintained that, to get approval for use on the NHS, medicines 'must not only provide benefits to patients but also represent a good use of NHS resources and taxpayers' money'. However, critics say a failure to raise the threshold in-line with inflation meant life-changing drugs were being blocked. Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry, said: 'There is growing evidence that it is becoming harder to bring new medicines to NHS patients. Increasingly, some new medicines may not be launched in the UK at all.' Companies including US giant Eli Lilly have said the regulator must rethink how 'value-for-money' is assessed. On Monday, a spokesman for the company said: 'The UK has historically focused on medicines as a cost to the NHS rather than evaluating their social and economic value.' Ministers are understood to be listening to demands from the industry for Nice to shake up its formula, with medicines such as AstraZeneca's breast cancer treatment Enhertu likely to be resubmitted for approval for NHS use if the formula is updated. Nice and AstraZeneca previously failed to reach an agreement over a price for the drug, which costs an estimated £118,000 per course of treatment. The NHS typically gets discounts, although the level is commercially sensitive. The Nice formula is being discussed after President Trump took a personal interest in the NHS issue. In trade documents between the US and UK, it said the NHS would review drug pricing to take into account the 'concerns of the president'. US officials are particularly concerned by an arrangement that sees companies pay revenue back to the NHS if costs rise faster than expected. Drug companies paid £3bn back to the NHS last year. In April, Wes Streeting, the Health Secretary, said he was proud that the UK had kept prices of medicines low. However, he admitted that the UK had become too focused on cost rather than the benefits in some cases. Mr Streeting said: 'We've moved from quite rightly trying to drive a good bargain on the price of drugs and treatment to a position where sometimes people view medicine spend as a dead weight cost'.

Instant Payments Regulation: Facing the Skeletons in the Closet
Instant Payments Regulation: Facing the Skeletons in the Closet

Finextra

timean hour ago

  • Finextra

Instant Payments Regulation: Facing the Skeletons in the Closet

Joining the FinextraTV Studio during EBAday 2025 were Serge Wagener, Member of the EBA Board and Chair of the EBA Practitioners Group on Instant Payments and Annick Moes, Head of Industry Issues, Cooperation Initiatives and Communications, EBA. Both Wagener and Moes pointed out ongoing challenges in implementing the Instant Payments Regulation (IPR), such as delivering Verification of Payee for bulk payments. Referencing their newest publication, they stressed how EBAday gave experts the opportunity to bring out the skeletons from the closet and discuss their implementation concerns with peers.

Why A Common Standard Is More Important Than A Common Technology
Why A Common Standard Is More Important Than A Common Technology

Finextra

timean hour ago

  • Finextra

Why A Common Standard Is More Important Than A Common Technology

In this FinextraTV interview at the 2025 EBAday in Paris, Tsvetanka Nankova, Managing Director, Global Head of Sales Institutional Cash & Trade Finance, Deutsche Bank visited the studio to discuss the future of data. Comparing the popularity of data conversations to those of AI, Nankova emphasises the importance of not taking data at 'face value' and instead interrogating its origins, compliance, accuracy, and relevance. On top of this, she explains the two-fold benefit of regulation like ISO 20022, explaining how a shared standard should be prioritised over a shared technology.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store